Robust immune response and protection against lethal pneumococcal challenge with a recombinant BCG-PspA-PdT prime/boost scheme administered to neonatal mice

Full metadata record
DC FieldValueLanguage
dc.contributor(LDV) Lab. Desenvolvimento de Vacinaspt_BR
dc.contributorPrograma de Pós-Doutoradopt_BR
dc.contributor.authorTrentini, Monalisa Martinspt_BR
dc.contributor.authorRodríguez, Duniapt_BR
dc.contributor.authorKanno, Alex Issamupt_BR
dc.contributor.authorGoulart, Cibellypt_BR
dc.contributor.authorDarrieux, Michellept_BR
dc.contributor.authorLeite, Luciana Cezar de Cerqueirapt_BR
dc.date.accessioned2024-03-19T14:01:17Z-
dc.date.available2024-03-19T14:01:17Z-
dc.date.issued2024pt_BR
dc.identifier.urihttps://repositorio.butantan.gov.br/handle/butantan/5281-
dc.description.abstractPneumococcal diseases are an important public health problem, with high mortality rates in young children. Although conjugated pneumococcal vaccines offer high protection against invasive pneumococcal diseases, this is restricted to vaccine serotypes, leading to serotype replacement. Furthermore, the current vaccines do not protect neonates. Therefore, several protein-based pneumococcal vaccines have been studied over the last few decades. Our group established a recombinant BCG expressing rPspA-PdT as a prime/rPspA-PdT boost strategy, which protected adult mice against lethal intranasal pneumococcal challenge. Here, we immunized groups of neonate C57/Bl6 mice (6–10) (at 5 days) with rBCG PspA-PdT and a boost with rPspA-PdT (at 12 days). Controls were saline or each antigen alone. The prime/boost strategy promoted an IgG1 to IgG2c isotype shift compared to protein alone. Furthermore, there was an increase in specific memory cells (T and B lymphocytes) and higher cytokine production (IFN-γ, IL-17, TNF-α, IL-10, and IL-6). Immunization with rBCG PspA-PdT/rPspA-PdT showed 100% protection against pulmonary challenge with the WU2 pneumococcal strain; two doses of rPspA-PdT showed non-significant protection in the neonates. These results demonstrate that a prime/boost strategy using rBCG PspA-PdT/rPspA-PdT is effective in protecting neonates against lethal pneumococcal infection via the induction of strong antibody and cytokine responses.pt_BR
dc.description.sponsorship(FAPESP) Fundação de Amparo à Pesquisa do Estado de São Paulopt_BR
dc.format.extent122pt_BR
dc.language.isoEnglishpt_BR
dc.relation.ispartofVaccinespt_BR
dc.rightsOpen accesspt_BR
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/pt_BR
dc.titleRobust immune response and protection against lethal pneumococcal challenge with a recombinant BCG-PspA-PdT prime/boost scheme administered to neonatal micept_BR
dc.typeArticlept_BR
dc.rights.licenseCC BYpt_BR
dc.identifier.doi10.3390/vaccines12020122pt_BR
dc.contributor.external(USF) Universidade São Franciscopt_BR
dc.identifier.citationvolume12pt_BR
dc.identifier.citationissue2pt_BR
dc.subject.keywordrecombinant BCGpt_BR
dc.subject.keywordneonatal micept_BR
dc.subject.keywordstreptococcus pneumoniaept_BR
dc.subject.keywordprime/boost strategypt_BR
dc.relation.ispartofabbreviatedVaccinespt_BR
dc.identifier.citationabntv. 12, n. 2, 122, jan. 2024pt_BR
dc.identifier.citationvancouver2024 Jan; 12(2):122pt_BR
dc.contributor.butantanTrentini, Monalisa Martins|:Pós-Doc|:(LDV) Lab. Desenvolvimento de Vacinas|:PrimeiroAutorpt_BR
dc.contributor.butantanRodríguez, Dunia|:Pesquisador|:(LDV) Lab. Desenvolvimento de Vacinaspt_BR
dc.contributor.butantanKanno, Alex Issamu|:Pesquisador|:(LDV) Lab. Desenvolvimento de Vacinaspt_BR
dc.contributor.butantanLeite, Luciana Cezar de Cerqueira|:Pesquisador|:(LDV) Lab. Desenvolvimento de Vacinas|:Autor de correspondênciapt_BR
dc.sponsorship.butantan(FAPESP) Fundação de Amparo à Pesquisa do Estado de São Paulo¦¦2017/24832-6pt_BR
dc.identifier.bvsccBR78.1pt_BR
dc.identifier.bvsdbIBProdpt_BR
dc.description.dbindexedYespt_BR
item.fulltextCom Texto completo-
item.languageiso639-1English-
item.grantfulltextopen-
item.openairetypeArticle-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.dept#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid0000-0001-6449-3359-
crisitem.author.orcid0000-0002-4731-1493-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.orcid0000-0003-0156-1312-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.author.parentorg#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.journal.journalissn#PLACEHOLDER_PARENT_METADATA_VALUE#-
crisitem.journal.journaleissn#PLACEHOLDER_PARENT_METADATA_VALUE#-
Appears in Collections:Artigos


Files in This Item:

vaccines-12-00122-v2.pdf
Description:
Size: 2.62 MB
Format: Adobe PDF
View/Open
Show simple item record

This item is licensed under a Creative Commons License Creative Commons